Rx-360 seeks to eliminate counterfeit, compromised drugs from supply chain

WASHINGTON Counterfeit and compromised drugs have become a problem, but a nonprofit organization launched earlier this month hopes to bring stakeholders from throughout the drug industry together to keep them out of the supply chain.

More than 125 people from 70 organizations representing the pharmaceutical, biotechnology and generic drug industries, as well as suppliers, trade organizations and regulatory agencies, attended the launch meeting of the Rx-360 International Pharmaceutical Supply Chain Consortium at Washington’s Ronald Reagan Building and International Trade Center.

“The organization was incorporated for the purpose of developing and implementing enhanced global quality systems and processes to help members ensure product quality and authenticity throughout their supply chains,” Mary Devlin Capizzi of Drinker Biddle & Reath told attendees.